In a single center experience, the maintenance therapy after CD19 CAR-T treatment achieved similar rate of overall survival (OS) and event-free survival (EFS) while being better-tolerated and lower-cost compared to HSCT in pediatric patients with B-ALL [11]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.